BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants another clinical trial for Duchenne muscular dystrophy treatment; focus moves to Sarepta's candidate, which gets committee review next week.